Mounting evidence suggests neuroinflammation is a key process in glaucoma, yet the precise roles are not known. Understanding these complex processes, which may also be a key in other common neurodegenerations such as Alzheimer's disease, will lead to targeted therapeutics for a disease that affects as many as 80 million people worldwide. Here, we define neuroinflammation as any immune-relevant response by a variety of cell types including astrocytes, microglia, and peripherally derived cells occurring in the optic nerve head and/or retina. In this review article, we first discuss clinical evidence for neuroinflammation in glaucoma and define neuroinflammation in glaucoma. We then review the inflammatory pathways that have been associated with glaucoma. Finally, we set out key research directions that we believe will greatly advance our understanding of the role of neuroinflammation in glaucoma. This review arose from a discussion of neuroinflammation in glaucoma at the 2015 meeting of The Lasker/IRRF Initiative for Innovation in Vision Science. This manuscript sets out to summarize one of these sessions; "Inflammation and Glaucomatous Neurodegeneration", as well as to review the current state of the literature surrounding neuroinflammation in glaucoma.
Introduction
An increasing body of literature, especially from various animal models, suggests neuroinflammation (generally considered to be immune responses relevant to the central nervous system (CNS)) is a key process in glaucoma (Xu et al., 2009; Baltmr et al., 2010; Chen et al., 2013; Soto and Howell, 2014) . However, the contribution neuroinflammation plays is not clear. To understand neuroinflammation in glaucoma, it is important to determine (a) what types of neuroinflammatory processes are involved, (b) which sites and which cell types are involved, (c) the timing of neuroinflammatory responses and (d) whether these processes are beneficial or damaging. It is important to note that, to date, much of the supporting data for a role of neuroinflammation in glaucoma has been generated in animal models. Therefore, moving forward, it is important to fully explore neuroinflammation in both human subjects and animal models relevant to glaucoma.
It is important to standardize the terminology when referring to neuroinflammation. In non-neural tissues, inflammation usually refers to an influx of leukocytes from the blood. In the CNS, 'neuroinflammation' is also used to refer to microglial, and in some cases, astrocyte, responses, without necessarily leukocyte influx from the blood. The difficulty is that almost all CNS pathology is accompanied by microglial responses, and so there is no longer a special term for classical inflammatory processes in the CNS, as occurs, for example, in infection or Multiple Sclerosis. Throughout this review, 'neuroinflammation' in glaucoma will be used to distinguish between inflammatory processes taking place in CNS-* This article summarizes the results of a targeted session on this topic at the March 2015 conference Astrocytes and Glaucomatous Neurodegeneration. This meeting was a follow-up to the 2010 meeting on the same topic, both of which were conducted as part of The Lasker/IRRF Initiative for Innovation in Vision Science. For more information about this conference, its participants and other review articles that originated from it see Tamm and Dowling, 2017 . A list of the other participants of the targeted session is provided at the end of this article.associated structures such as the retina and optic nerve head (ONH), from inflammation in other locations in the eye such as the anterior compartments that may be more relevant to intraocular pressure (IOP) elevation.
The main body of the article (2. Neuroinflammation in glaucoma) is divided into four parts that reflect the following main topics: clinical relevance (2.1), the major sites to consider (2.2), the cell types involved (2.3), and the neuroinflammatory processes that seem worthy of further investigation (2.4). We stress that this article is not an extensive review of the literature; it is more a summary of the discussions that took place during the meeting. For those interested in a more comprehensive review of the literature, we recommended a number of relevant review articles (e.g., References (Wax and Tezel, 2009; Ren and Danias, 2010; Nickells et al., 2012; Vohra et al., 2013; Kuehn, 2014; Soto and Howell, 2014 ) and see Fig. 1 ). The article ends with suggestions on the most impactful and achievable 5-year goals moving forward (part 3).
Neuroinflammation in glaucoma

Clinical relevance of neuroinflammation in glaucoma
Paradoxically, both ocular inflammation (uveitis) and the treatment of inflammatory conditions with steroids can both lead to glaucoma. In the case of uveitis, a form of glaucoma called inflammatory, or uveitic, glaucoma can result from obstruction of drainage structures in the anterior segment as a secondary consequence of the ocular inflammation (Bodh et al., 2011; Siddique et al., 2013; Baneke et al., 2015) . In the case of steroid-induced glaucoma, the steroids are generally thought to be deleterious, not by their action in reducing inflammation, but rather by acting directly to affect the drainage structures, among other things, by increasing extracellular matrix deposition by trabecular meshwork cells, which increases outflow resistance and consequently increased intraocular pressure (Clark et al., 1995; Tektas et al., 2011; Overby et al., 2014; Raghunathan et al., 2015; Taurone et al., 2015) . This paradoxical relationship between inflammation and glaucoma (both inflammation and anti-inflammatory treatment can give you glaucoma), together with the absence of obvious large-scale lymphocyte infiltration into the retina (Yang et al., 2001; Tezel and Wax, 2004) , have contributed to the generally held notion among clinicians that human glaucoma is not an inflammatory disease. And yet, many studies have reported microglial responses in glaucoma, which are considered neuroinflammation in other neurodegenerative disorders (Tezel and Wax, 2004; Johnson et al., 2007; Bosco et al., 2011; Howell et al., 2011; Johnson et al., 2011; Astafurov et al., 2014; Bosco et al., 2015) .
Indeed, a significant fraction of glaucoma patients have small optic disk hemorrhages visible upon ophthalmic examinations, which are generally associated with disease progression (Airaksinen and Heijl, 1983; Drance, 1989; Gordon and PiltzSeymour, 1997; Wang et al., 2006; Uhler and Piltz-Seymour, 2008; De Moraes et al., 2012) . Given that only those bleeds that are seen during the very brief time that patients are undergoing ophthalmic examinations are considered (and only those in front rather than behind the lamina cribrosa would be visible), it is quite possible that small focal bleeds may occur in most and maybe all glaucoma patients (Law et al., 2001 ). Since hemorrhages necessarily mean that there is a breach of the blood-retina barrier, circulating immune cells certainly enter the retina, including in the nerve fiber layer where these hemorrhages are most common (Drance, 1989; Choi et al., 2007; Jeoung et al., 2008; Kurvinen et al., 2010; Hwang et al., 2014) , which is the layer in the retina carrying the delicate axons which are damaged in glaucoma. So, are these hemorrhages a red herring, or are they evidence that a focal inflammatory event has occurred? Such lesions could certainly cause damage to axons. Even if they are not the primary event, they may contribute to the spread of a more focal insult, or, alternatively, they may just be reporting the occurrence of some other neuroinflammatory event. What would happen if optic disk hemorrhages where in some way prevented? Maybe nothing, maybe glaucoma damage would be more severe, or maybe glaucoma would be prevented.
Optic nerve vasculature is also special in terms of its permeability so that could provide another mechanism for contact of axons with immune cells or other immune system non-cellular components.
The infiltration of circulating monocytes, which can occur transiently and focally in many if not most glaucomas, is just one feature of neuroinflammation. There is extensive data that both the cellular hallmarks of neuroinflammation, astrogliosis and microgliosis, are also parts of the human disease. Both in the retina and, most importantly in the ONH, the principal microglial cells show signs of increased reactivity in glaucoma (Bosco et al., 2011; Howell et al., 2011; Qu and Jakobs, 2013; Seitz et al., 2013; Howell et al., 2014) . Similarly, the microglia also become highly reactive in the human disease, extensively so in the ONH (Neufeld, 1999; Yuan and Neufeld, 2001) . Furthermore, numerous pathways now known to be critical regulators of neuroinflammation have been shown to show gene-expression differences in glaucoma, or to confer genetic risk to developing glaucoma, as is discussed further below. Thus, not only is there likely infiltration of circulating monocytes, but the more chronic signs of neuroinflammation are also present in human glaucoma.
Thus, it may be time to abandon the notion that glaucoma does not have an inflammatory component. It is time to ask what kind of neuroinflammation occurs, where does it occur, is it relevant to disease progression, and, most importantly, whether modulation of the neuroinflammation can be used therapeutically. In light of animal studies that are beginning to show that modulation of neuroinflammation may be a promising therapeutic strategy (Bosco et al., 2008; 2012; Howell et al., 2011 Howell et al., , 2012 Howell et al., , 2013 2014) , the group felt a renewed effort to study neuroinflammation in human glaucoma is warranted. There certainly are hurdles to incorporating clinical diagnostics of inflammation into routine glaucoma practice that cannot be ignored. Glaucoma is asynchronous in the two eyes, and different parts of the retina and optic nerve are going through different phases of the disease process at any one time. So, when and where is the best place to look for neuroinflammation? Is neuroinflammation part of the problem, or is it a self-defense mechanism without which disease would progress more quickly? What are the relevant cells to look atdthe rare circulating monocytes that may be transiently entering the retina or the resident glial populations? There are new molecular markers, new molecular techniques, and new imaging modalities that would make answering these questions much easier now than even a few years ago. These tools should be used to study neuroinflammation in glaucoma. The preponderance of the basic science data supports the study of neuroinflammation as both a potential diagnostic tool and a potential therapeutic target. However, researchers and clinicians remain divided as to the relevance of neuroinflammation in glaucoma. We believe this may be due to the fact that the majority of evidence for a role of neuroinflammation in glaucoma has come primarily from a variety of different animal models e as opposed to human studies. While studies in animal models benefit from the ability to study onset and early progression of glaucoma, human studies to date have come from a small number of end-stage, postmortem studies that might not truly reflect the full extent of inflammation in glaucoma. Therefore, more detailed assessment in early stages of human glaucoma using modern imaging modalities is required to bridge this divide.
Defining the sites of neuroinflammation in glaucoma
Neuroinflammation related to glaucoma can occur in many different sites, including (i) posterior compartments of the eye (e.g., retina, ONH); (ii) optic tract and brain (e.g., superior colliculus and lateral geniculate), and (iii) peripherally in the blood, bone marrow or other tissues. However, discussions focused on regions felt by the group to be most relevant to glaucoma: retinal ganglion cell (RGC) dysfunction/loss; the ONH, where many studies have shown critical events occur in glaucoma; the retina, where RGC soma, dendrites and synapses maybe affected by neuroinflammation, and the peripheral immune system. Recent studies have shown infiltration of leukocytes into the ONH and retina may be key events in glaucoma Astafurov et al., 2014) .
Defining neuroinflammatory cells in glaucoma
It has been long thought that the axons of RGCs are the first structures to be insulted during glaucoma pathogenesis, although the initial trigger that causes this insult is unknown. Mechanical alteration to the lamina cribrosa, changes in neurotrophic signaling, direct pressure on RGCs, and activation of glial cells (astrocytes and/ or microglia) are all potential factors that drive this damage. Astrocytes (both in the ONH and retina), Müller glia, and microglia are the 'resident cells' that perform innate immune-like functions in the retina and/or ONH. In healthy tissues, astrocytes occupy discrete domains and help preserve a homeostatic environment for neurons to function, in part, through the maintenance of the neurovascular unit (Grieshaber et al., 2007; del Zoppo, 2010 del Zoppo, , 2012 Kur et al., 2012; da Fonseca et al., 2014) . Activation of astrocytes is commonly termed reactive astrocytosis, which refers to a broad spectrum of changes from subtle changes in the morphology (thickening of astrocyte processes) to proliferation and migration of astrocytes to sites of injury where they can form a glial scar. Both subtle and severe astrocytosis, including the induction of inflammatory pathways, have been reported in ONH astrocytes during glaucoma, with some studies suggesting they may be among the earliest changes (Dai et al., 2012; Sun et al., 2013; Soto and Howell, 2014; Schneider and Fuchshofer, 2015) . Recent data also show that ONH astrocytes are phagocytic (Nguyen et al., 2011; Mills et al., 2015) . However, further work is needed to determine whether these changes are damaging or beneficial. Microglia are the main professional phagocytes of the central nervous system and survey the environment for perturbations, responding quickly to restore homeostasis. They are often considered first responders to infection and injury, activating a number of inflammatory pathways and inducing inflammatory responses in other cells such as astrocytes (discussed in section B4). Studies show that microglia increase in numbers and become activated in human and animal models of glaucoma, but it is unclear if these responses are protective, pathogenic, or both. There is some evidence that retinal and ONH microglia deactivation by minocycline at early stages of disease may result in reduced neurodegeneration (Shimazawa et al., 2005; ; Bosco et al., 2008; Levkovitch-Verbin et al., 2011; 2014a; 2014b; Huang et al., 2013) . Also, macrophage (or monocyte) infiltration have been shown to be coincident with the onset of glaucoma in the DBA/2J mouse ; furthermore, irradiated DBA/2J mice, which lack infiltrating monocytes, do not develop glaucoma. This observation raises the possibility that monocyte infiltration may be causative in glaucoma, although whether similar monocyte infiltration occurs in human glaucoma has not yet been substantiated. However, monocyte infiltration is a common event in other neurodegenerative diseases, suggesting it may also occur in human glaucoma. It is also worth noting the neuroinflammation occurs in the aging brain and involves multiple cell types, including astrocytes, microglia and macrophages ( (Streit and Xue, 2014; Ward et al., 2015) , Fig. 2) . Furthermore, given that aging is a major risk factor for glaucoma and neuroinflammation increases with age, the role of age-related neuroinflammation needs to be studied in glaucoma. Overall, the group felt that an important goal was to identify the neuroinflammatory cells in human glaucoma; then, animal models could be used to identify therapeutic strategies to target the cells for the treatment of glaucoma.
Inflammatory pathways in glaucoma
There are a number of molecular pathways that are key regulators of neuroinflammation that in both humans and animal models have been implicated in the etiology of glaucoma. Here we focus on the complement cascade, the Toll-like receptors, and Tumor Necrosis Factor a pathway. In addition to these, interferons, interleukins, and various other pro-and anti-inflammatory cytokines (Wakefield and Lloyd, 1992; Tezel, 2008; Huang et al., 2009; Agarwal and Agarwal, 2012; Al-Gayyar and Elsherbiny, 2013; Krizaj et al., 2014) , and pathways involved in antigen presentation to T cells (Yang et al., 2001; Gramlich et al., 2015; Wong et al., 2015) , such as b2-microglobulin and CD3, are likely involved in glaucoma, or at least in RGC damage in animal models of glaucoma.
The complement cascade is one of the key pathways in an evolutionary ancient immune system called the innate immune system, which helps to detect both pathogens and cellular damage. Various components of the complement system are increased in both human glaucoma (Stasi et al., 2006; Nikolskaya et al., 2009; Tezel et al., 2010; Doudevski et al., 2014 ) and animal models of glaucoma (Howell et al., 2008; Ren and Danias, 2010; Howell et al., 2011; Howell et al., 2013; Astafurov et al., 2014; Howell et al., 2014) , as well as in the aging retina (Xu et al., 2009 ). There are three arms to the complement system that generally respond to different types of stimuli: the classical, alternative and lectin pathways. All pathways have multiple inputs and outputs and are subject to a high degree of regulation. To date, most evidence points to pronounced activation of the classical pathway in glaucoma (Stasi et al., 2006; Stevens et al., 2007; Fan et al., 2010; Howell et al., 2011; Astafurov et al., 2014) . In the classical complement pathway, damaged or damaging stimuli, which can derive from dead or damaged cells, are tagged by the C1 complex. This then triggers activation of the C3 convertase, which produces the first of several complement peptides that can directly recruit blood leukocytes to the site of complement activation. C3 convertase activity also leads to activation of the C5 convertase, which produces further peptides that recruit leukocytes, but also the components that form the membrane attack complex (MAC) that lyses cells. An overly simplified view of the complement pathway in animal models of glaucoma is that the RGCs themselves sense the damage and respond by activating C1; the activation of C3 convertase requires glial cells such as astrocytes, which can, among other things, use the complement pathway to amplify the RGC distress signal to alert microglia and, if needed, to recruit monocytes. Interestingly, the complement pathway in glaucoma appears to be activated principally in two placesdthe ONH, the likely site of the blinding insult, and in the inner plexiform layer, where it may be involved in pruning RGC dendrites. The complement pathway plays a similar synaptic pruning function during normal CNS development (Stevens et al., 2007) . Both in the ONH, but especially so in the inner plexiform layer, it is quite possible that activation of the complement pathway is not responsible for killing RGCs, but rather acts either to prevent further damage to RGCs or to maintain RGC function in the face of disease. This double-edged sword nature of the complement pathway may explain why in some animal models of glaucoma but not in others, complement components have a strong pathogenic role (Stasi et al., 2006) . It is also worth noting that, unlike in human macular degeneration, where genome-wide association studies have provided strong evidence for a prominent role for the complement system, the same has not been true for similar studies in human glaucoma. Toll like receptors (TLRs) have also been implicated in the pathogenesis of glaucoma in two ways: certain alleles of the TLR4 gene are associated with an increased risk of glaucoma, at least in some populations (Shibuya et al., 2008; Takano et al., 2012) , and TLR4 and other TLRs are reported to be increased in glaucoma retinas . TLRs are one of the principal receptor systems to recognize Pathogen-and Damage-Associated Molecular Patterns (PAMPS and DAMPs). Different TLRs are tuned to respond to the presence of different stimuli that are not found in normal tissues other than when there is disease or damage; for example, TLR3 responds to microbial double-stranded RNA, and TLR4 responds to endogenous ligands induced by cell stress such as heat shock proteins (HSPs). Interestingly, one of the endogenous ligands for TLR4 is Tenascin-C, which is highly upregulated in glaucomatous ONH (Pena et al., 1999; Wallace et al., 2014; 2015) and animal models of glaucoma (Johnson et al., 2007) . Not surprisingly, astrocytes have a more limited set of damage-detecting TLRs than microglia and monocyte/macrophages. While there have been a few studies of TLRs in animal models of RGC injury, at this point it is unclear what role TLRs have in human glaucoma.
Tumor necrosis factor alpha (TNFa) is another neuroinflammation modulator for which there is strong evidence of involvement in glaucoma. Certain polymorphisms in TNFa confer an increased risk of glaucoma (Lin et al., 2003; Mossb€ ock et al., 2006; Bozkurt et al., 2012; Wang et al., 2012; Xin et al., 2013; Dubey et al., 2015) . Moreover, there is extensive data showing increased TNFa in vitreous, retina and optic nerve in glaucoma (Wakefield and Lloyd, 1992; Yuan and Neufeld, 2000; Tezel, 2008; Yang et al., 2011; Wiggs, 2015) . Interestingly, the TNFa is produced by astrocytes and especially microglia (Sawada et al., 1989; Hostenbach et al., 2014) . Generally, secretion of TNFa and a related protein FasL are thought to promote RGC cell death, through a variety of mechanisms (Wajant et al., 2003; Mac Nair et al., 2014; Cueva Vargas et al., 2015) , which most likely involve direct killing of RGCs. To this, intravitreal injections of soluble murine TNFa induces oligodendrocyte and RGC death in a mouse model of glaucoma, and using specific TNFa blockers protects from RGC loss in a rat model of glaucoma (Nakazawa et al., 2006; Cueva Vargas et al., 2015) . Why glia should have a mechanism killing RGCs is not obvious. Pharmacological inhibition of TNFa or FasL activity has been shown to be neuroprotective in animal models of glaucoma (Roh et al., 2012; Su et al., 2014) , although these inhibitors have not provided protection in other neurodegenerative disorders. Given the wide availability of TNFa inhibitors approved for human use, they deserve further study in relation to human glaucoma; more studies, for example, are needed to determine precisely when and where TNFa is secreted in glaucoma.
Overall, although multiple neuroinflammatory pathways and genes have been identified in human and animal models of glaucoma (Fig. 1) , much work is still to be done to determine when they are activated and which ones are protective and which ones are pathogenic. As their roles become clearer, it should become clearer which ones may be therapeutic targets in human glaucoma.
3.
Moving forward e recommended five-year goals
Determine the repertoire of neuroinflammatory cells and pathways in human glaucoma
The lack of assessment of neuroinflammation in human glaucoma is a key area that needs to be addressed. To achieve this, researchers need to properly utilize existing human and non-human primate glaucomatous tissues, using the best immunohistochemistry markers and microscopy. Improved availability and standardization of tissue sources, with as much associated data as possible, will aid these efforts. A significant challenge is to assess the range of neuroinflammatory cell types present in human glaucoma e particularly those cell types that may play a role early in disease but may be present in extremely low numbers. Often, tissue is obtained from patients with later stages of glaucoma, which may be less useful. New markers for distinguishing microglia from macrophages will be especially important in future studies.
Interrogation of genome-wide datasets to identify neuroinflammatory cells and genes in human glaucoma
During the last 10 years, the ability to identify genetic variants using new genetic tools has increased dramatically, and the cost of these experiments has dropped greatly. In glaucoma and a myriad of other likely-relevant human diseases, there is an increasing number of genome-wide datasets available, including genomewide association studies, whole genome and exon sequences, and transcriptomes, which can be mined for genes that provide links between neuroinflammation and glaucoma. Accessibility of these datasets, and datasets from other neurodegenerative and immunerelated diseases, will be important, as will be the platforms to mine the data. Where possible and appropriate, these datasets should be made widely accessible to interrogation by multiple researchers.
What are the triggers and drivers of neuroinflammation in glaucoma?
There are likely to be both local and peripheral inflammatory triggers, and these are likely to vary with age, genetics and the environment. There are many potential candidates, including cellular debris, nuclear DNA and mitochodrial DNA derived from cell debris, misfolded proteins, ATP release, proinflammatory cytokines, local microbial flora (oral, gastrointestinal, ocular) and peripheral inflammatory events. In addition, much work is still required to understand the neuroinflammatory genes (e.g. TNFa, TGFb, APOE) and pathways (e.g., complement cascade, TLR family and interferon family).
Define the contribution of age-related neuroinflammation to glaucoma susceptibility and pathogenesis
Age is the major risk factor for glaucoma, and yet little is know about how the aging process increases risk. Neuroinflammatory responses have been shown to increase in the brain during aging, and, if the same is true in the ONH and retina, these responses may contribute to an increased susceptibility to glaucoma.
The role of the microbiome in glaucoma
Growing evidence suggests the microbiome plays a critical role in some complex diseases (Fig. 3) . This is likely to be the case in glaucoma, and a few studies are now being performed to explore this possibility. Animal models can play a role in this area, as it is known that individual animal colonies often respond very differently to the same stimulus or mutation, which may be due in large part because of differences in their microbiomes.
Continued development of animal models relevant to ocular hypertension and glaucoma
At the Initiative in 2010, 'Animal Models' was a full session, and new models have emerged since then, including both genetic (MYOC) and inducible (mouse and rat bead models and various virus models). In addition to continued efforts to characterize and improve existing models, there is still a pressing need for the development of new models, especially new genetic animal models based on big-effect human mutations that greatly increase the risk of open angle glaucoma. No animal model is going to fully recapitulate all aspects of glaucoma, particularly given the heterogeneous nature of human glaucoma. However, it is important that models are used appropriately and characterized as extensively as possible.
Our idea of an appropriate species to model aspects of human glaucoma should not just be limited to mammals e a lot of valuable information, particularly relating to the function of genes and pathways relevant to glaucoma can be obtained from other organisms such as flies, worms, frogs and fish. The development of genome editing, particularly CRISPR/CAS9, has revolutionized our ability to manipulate genomes of potentially any species. Therefore, for the first time, genetic models relevant to glaucoma can be generated in many species with relative ease. Novel risk genes (such as ABCA1 and CDKN2A-AS) are being linked and associated with glaucoma through genome-wide association studies and exon and genome sequencing efforts, but little is known about how they contribute to glaucoma. Therefore, using genome editing, candidate genes can be manipulated in multiple species to understand how variations in these genes increase susceptibility to human glaucoma. Ultimately though, for preclinical studies, additional models in various mammals are still required. During the general discussion at the end of the meeting, it was exciting to hear from a number of investigators that efforts are underway to establish new glaucoma models in mammals with a lamina cribrosa that are easier and more cost effective to use than the larger non-human primates currently being used. These efforts should be encouraged. Overall, the group was highly positive that the next few years will bring novel insights into the role that neuroinflammation plays in glaucoma, and that, in so doing, we will come closer to being able to treat, and maybe even prevent, all vision loss due to glaucoma.
List of participants Fig. 3 . The human microbiome may affect glaucomatous neurodegeneration. (A) Differences in oral bacterial load in a cohort of African-American patients with and without glaucoma. Normalized oral bacterial load (NOBL) of patients with glaucoma were higher than those of subjects without glaucoma (p < 0.017, t-test). Although cases were significantly different from controls in age (p < 0.008, t-test), gender (p < 0.02 Chi-square) and diabetes status (p < 0.021, Chi square), GLM ANOVA of NOBLs (using group, gender, diabetes status and age [above or below median value] as independent variables) revealed a significant effect of group status (whether a subject belonged to cases or controls) only (p < 0.024) while all other parameters did not show a statistically significant effect (p > 0.26 for all). B. Microbial components affect neurodegeneration in glaucoma animal models. Peripheral lipopolysaccharide (LPS) administration significantly accelerates glaucomatous pathology in DBA/2J mice (but not in the non-glaucomatous DBA/2J-Pe mice) as well as in the microbead-induced IOP elevation model of glaucoma in C57BL/6 mice (not shown here). LPS (60 mg) was injected into one hind footpad of 6-month old male DBA/2J and DBA/2J-Pe mice and retinal damage was assessed at 8 months of age. Computer-assisted counts of total RGCs per retina (n ¼ 18 and n ¼ 24 retinas for DBA/2J and DBA/2J þ LPS, respectively; n ¼ 4 and n ¼ 10 retinas for DBA/2J-Pe and DBA/2J-Pe þ LPS, respectively) show increased RGC loss in DBA/2J mice treated with LPS. Data are presented as mean ± SEM. Statistical differences were assessed by one-way ANOVA, followed by TukeyKramer post-hoc testing (**p < 0.01). Adapted from Astafurov et al, 2014. 
